About Magnolia Limited
Magnolia Limited is a Healthcare company based in Mumbai (India) founded in 2010. It specializes in API synthesis for pharmaceutical applications. It operates on a B2B model. The company has 1 employees. Its Indian entity Magnolia Limited reported revenue of ₹3.72 Cr. Its focus areas include Healthcare and Pharmaceuticals, Pharmaceuticals, API Manufacturing and Synthesis Services. Similar companies include Laurus Labs, Symbiotec, Provepharm Life Solutions, Beijing Biostar Technologies and SeQuent and 4 more; 4 of its 9 listed similar companies have raised funding.
Company details
Magnolia Limited, founded in 2010 in Mumbai, India, focuses on healthcare and pharmaceuticals, producing pharmaceutical products, api manufacturing, and synthesis services. Specializes in API synthesis for pharmaceutical applications. The company is dedicated to excellence, innovation, and customer satisfaction, ensuring sustainable practices and long-term success in its sectors.
- Headquarters Mumbai, India
- Employees 1
- SectorsHealthcare
- Website magnolialimited.com
- Legal Name Magnolia Limited
- Date of Incorporation 02 Sep, 2010
- Jurisdiction Mahad, Maharashtra, India
- Annual Revenue₹3.72 Cr
FY 2017 · -94% YoY
- Net Loss-₹13.94 Cr
FY 2017 · -375% margin
- EBITDA-₹10.84 Cr
FY 2017 · -291% margin
- Employee Count1
Associated legal entities of Magnolia Limited
Magnolia Limited operates through Magnolia Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2017) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Magnolia Limited CIN U24100MH2010PLC207402 | Active | 02 Sep 2010 | Mahad, Maharashtra | ₹3.7 Cr | – | 3 | View details |
Board of directors of Magnolia Limited (Magnolia Limited)
Magnolia Limited is the primary company behind Magnolia Limited. The board of Magnolia Limited currently have 3 directors; the longest-serving is Reshma Ranjan Singh, appointed in 2010. 4 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Reshma Ranjan Singh DIN 03085053 | Additional Director | 02 Sep 2010 | 16 yrs 1 mo | Magnolia Limited |
| Treesha Sandeep Shetty DIN 06456574 | Whole-time director | 05 Sep 2013 | 13 yrs 1 mo | Magnolia Limited |
| Yogendra Singh DIN 03146184 | Additional Director | 17 Mar 2016 | 10 yrs 7 mo | Magnolia Limited |
Financials of Magnolia Limited
Figures of Magnolia Limited, the primary company behind Magnolia Limited, for FY 2017. Revenue was ₹3.72 Cr (-94% year on year). Net loss was -₹13.94 Cr (-375% margin). EBITDA was -₹10.84 Cr (-291% margin). Revenue has grown at a compounded annual rate of -40% over three years.
- ₹3.72 CrRevenue · FY 2017 · -94% YoY
- -₹13.94 CrNet loss · -375% margin
- -₹10.84 CrEBITDA · -291% margin
- ₹1.40 CrPaid-up capital
- -40%Revenue CAGR, 3 years
Balance sheet, profit and loss, cash flow and ratios of Magnolia Limited are on its company page.
Detailed financial statements for Magnolia Limited
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Similar companies to Magnolia Limited
Magnolia Limited has 9 listed similar companies in our database, 4 of them funded. They include Laurus Labs, Symbiotec, Provepharm Life Solutions, Beijing Biostar Technologies and SeQuent, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| lauruslabs.com | 2005 | Hyderabad, India | $229.73M | 6,035 | Pharmaceutical and biotechnology company | |
| symbiotec.in | 2002 | Indore, India | $61.01M | 1,822 | Non-sterile steroid hormone-based APIs and intermediates are manufactured. | |
| provepharm.com | 1998 | Marseille, France | $145.93M | – | APIs and drug products are developed and valorized in pharmaceuticals. | |
| biostar-pharm.com | 2002 | Beijing, China | $135.23M | – | APIs, intermediates, and biochemical reagents are developed and manufactured. | |
| sequent.in | 2002 | Bengaluru, India | – | – | APIs are developed and manufactured for therapeutic areas. | |
| sterlingpharmasolutions.com | 2016 | Dudley, United Kingdom | – | 560 | Contract development, manufacturing, and analytical services for APIs are offered. | |
| snapdragonchemistry.com | 2014 | Cambridge, United States | – | 43 | Drug discovery and development service provider | |
| jubilantpharma.com | 1978 | Noida, India | – | – | Pharmaceuticals, APIs, and radiopharmaceuticals are manufactured by the company. | |
| hikal.com | 1988 | Mumbai, India | – | 355 | APIs and intermediates are produced via custom synthesis and research. |
Detailed similar companies of Magnolia Limited
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Pharmaceuticals & Distribution
10 companies that operate in the same segment as Magnolia Limited (Pharmaceuticals & Distribution), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Pharmaceutical products are manufactured and marketed worldwide. | 1891 | Kenilworth, Warwickshire, United Kingdom | – | USD 64.93 B | 781 | |
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed. | 2014 | New York, New York, United States | USD 1.3 B | USD 8.26 M | 750 | |
Developer of pharmaceutical products for treating multiple diseases | 1980 | Thousand Oaks, California, United States | – | USD 33.23 B | 28,000 | |
Biopharmaceutical research and drug development are conducted globally by AbbVie. | 2012 | Chicago, Illinois, United States | – | USD 61.16 B | 55,000 | |
Traditional pharmaceutical medicines are developed for multiple health fields. | 1876 | United States | – | USD 65.18 B | 47,000 | |
Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others | 1987 | Foster City, California, United States | – | USD 29.45 B | 17,600 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 213.52 M | USD 29.62 M | 225 | |
Developer of medical devices, generic pharmaceuticals, and nutrition products | 1888 | Libertyville, Illinois, United States | – | USD 44.33 B | 3,710 | |
Medicines and health products are retailed through pharmacy outlets. | 2006 | Hyderabad, Telangana, India | USD 268.78 M | USD 734.57 M | 25,010 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Magnolia Limited
Magnolia Limited was founded in 2010.
Magnolia Limited is headquartered in Mumbai, India. It is registered at Mumbai, Maharashtra, India.
Magnolia Limited has 1 employees.
The primary company behind Magnolia Limited, Magnolia Limited, reported revenue of ₹3.72 Cr for FY 2017, down 94% year on year.
Magnolia Limited, founded in 2010 in Mumbai, India, focuses on healthcare and pharmaceuticals, producing pharmaceutical products, api manufacturing, and synthesis services. Specializes in API synthesis for pharmaceutical applications. The company is dedicated to excellence, innovation, and customer satisfaction, ensuring sustainable practices and long-term success in its sectors.
Magnolia Limited's top competitors include Laurus Labs, Symbiotec and Beijing Biostar Technologies.
Magnolia Limited operates through Magnolia Limited.
The legal entities of Magnolia Limited currently have 3 directors, including Reshma Ranjan Singh, Treesha Sandeep Shetty, Yogendra Singh.